Sensorion SA (FRA:RFM)

Market Cap	120.70M +5.2%
Revenue (ttm)	5.81M -12.6%
Net Income	-29.43M
EPS	-0.10
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.1924
Previous Close	0.2010
Day's Range	0.1924 - 0.1924
52-Week Range	0.1902 - 0.6500
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 1, 2026

About Sensorion

Sensorion SA, a biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France. The company develops SENS-501, a dual AAV vector gene therapy development product for restoring hearing in patients with mutations in OTOF gene in Phase 1/2 clinical trials; and SENS-601, a candidate for the treatment of hearing loss caused by mutations of the GJB2 gene in preclinical studies. It is also developing SENS-40, a small molecule in Phase 2b clinical trials to treat sudden sensorineural...

• Industry: Pharmaceutical Preparations
• Founded: 2009
• Employees: 63
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: RFM

Financial Performance

In 2025, Sensorion's revenue was 5.81 million, a decrease of -12.61% compared to the previous year's 6.65 million. Losses were -29.43 million, 13.3% more than in 2024.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jun 27, 2026

Data Sources Report a data error